Pharmaceutical

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract – Now 12-Month Data

CARDIFF, UK / ACCESSWIRE / July 11, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company developing a…

1 year ago

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas TherapeuticsFirst instance decision on…

1 year ago

Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024

LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2024 financial…

1 year ago

A Single Drug Against Multiple Respiratory Virus Infections – COVID, RSV, Influenza, Bird Flu – Planning Next Phase of Clinical Trials, Says NanoViricides

SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader…

1 year ago

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

CINCINNATI, Ohio, July 11, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced it has…

1 year ago

Fortrea Appoints Robert Parks as Chief Accounting Officer

DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced…

1 year ago

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated…

1 year ago

Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational

Largest expansion in company’s 150+-year history opensMajor client project already underway; new clients actively being onboarded LAUPHEIM, Germany and MILFORD,…

1 year ago

Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report

Addresses frequently asked questions on biosimilar interchangeability and its exclusivity Includes an interview with Scripius’ pharmacy benefit manager on their…

1 year ago

Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel…

1 year ago